法国队列研究:移植后淋巴增殖性疾病后再次肾移植
该研究回顾性分析了1998至2015年法国所有成人肾移植中心中,移植后淋巴增殖性疾病(PTLD)后再次接受肾移植的患者数据。共纳入52例患者,接受55次再次肾移植。从PTLD到再次移植的中位时间(原文为均值±标准差)为100±44个月。仅1例患者在再次移植后24个月出现PTLD复发,其余51例未复发。结论认为,在法国接受再次肾移植的患者中PTLD复发罕见。
要点
- PTLD后再次肾移植在法国队列中PTLD复发罕见,仅1例复发。
- 再次移植时98%患者EB病毒血清学阳性。
- 免疫抑制方案以钙调磷酸酶抑制剂+霉酚酸酯+激素最常见。
核心结论
- 在法国接受再次肾移植的PTLD患者中,PTLD复发是罕见事件。
研究设计与样本
- 回顾性队列研究,纳入1998至2015年法国所有成人肾移植中心中PTLD后再次肾移植的患者,共52例患者、55次再次肾移植。
主要发现
- 从PTLD到再次移植的时间为100±44个月(范围28-224个月)。
- 再次移植时98%的患者EB病毒血清学阳性。
- 48例患者使用了诱导治疗,其中17例(31%)接受胸腺球蛋白,31例(57%)接受IL-2受体拮抗剂。
- 6例患者接受利妥昔单抗治疗,53%的患者接受抗病毒药物。
- 1例患者在再次移植后24个月出现PTLD复发,51例患者未复发。
临床怎么用
- 对于有PTLD病史的肾移植候选者,再次肾移植后PTLD复发风险较低,可考虑进行再次移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Post-transplant lymphoproliferative disorders arising after kidney transplantation portend an increased risk of morbidity and mortality. Retransplantation of patients who had developed post-transplant lymphoproliferative disorder remains questionable owing to the potential risks of recurrence when immunosuppression is reintroduced. Here, we investigated the feasibility of kidney retransplantation after the development of post-transplant lymphoproliferative disorder. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We reviewed the data from all patients who underwent kidney retransplantation after post-transplant lymphoproliferative disorder in all adult kidney transplantation centers in France between 1998 and 2015. RESULTS: We identified a total of 52 patients with kidney transplants who underwent 55 retransplantations after post-transplant lymphoproliferative disorder. The delay from post-transplant lymphoproliferative disorder to retransplantation was 100±44 months (28-224); 98% of patients were Epstein-Barr virus seropositive at the time of retransplantation. Induction therapy for retransplantation was used in 48 patients (i.e., 17 [31%] patients received thymoglobulin, and 31 [57%] patients received IL-2 receptor antagonists). Six patients were also treated with rituximab, and 53% of the patients received an antiviral drug. The association of calcineurin inhibitors, mycophenolate mofetil, and steroids was the most common maintenance immunosuppression regimen. Nine patients were switched from a calcineurin inhibitor to a mammalian target of rapamycin inhibitor. One patient developed post-transplant lymphoproliferative disorder recurrence at 24 months after retransplantation, whereas post-transplant lymphoproliferative disorder did not recur in 51 patients. CONCLUSIONS: The recurrence of post-transplant lymphoproliferative disorder among patients who underwent retransplantation in France is a rare event.
引用
- Caillard S, Cellot E, Dantal J, et al. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. Clin J Am Soc Nephrol. 2017. PMID: 28818847. doi:10.2215/CJN.03790417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。